The Woman Who Was Told to Come Back When She Felt Worse
56-Year-Old Female · Hypertension · Hypothyroidism · Abnormal EKG
She saw a cardiologist. She had an abnormal EKG, elevated blood pressure, and years of borderline labs. Her echocardiogram was read as normal. She was told to come back ‘as needed.’ She came to Pulse Perfect for a second opinion. What the evaluation revealed illustrated one of the most persistent problems in cardiology: the systematic under-screening of women.
Female patients are statistically under-screened and under-treated in cardiovascular medicine. ‘Normal echo’ is not the same as ‘no cardiovascular disease.’
What Did Traditional Medicine Say?
Traditional Cardiology
- Echocardiogram: normal → 'come back as needed'
- Abnormal EKG noted but not further investigated
- Borderline LDL (122) and HbA1c (6.1%) → lifestyle advice only
- Lp(a) never tested
- Body composition and fitness capacity never assessed
- No further imaging ordered — follow up 'as needed'
Pulse Perfect Approach
- Echo revealed concentric LV hypertrophy, diastolic dysfunction, and left atrial dilation
- Stress test was nondiagnostic (baseline EKG abnormalities) → correctly prompted coronary CTA
- Coronary CTA: early LAD plaque confirmed → ASCVD diagnosis → statin + GLP-1 initiated
- Lp(a) = 88.3 nmol/L — a major independent genetic risk factor, never captured on standard panels
- VO₂ max: 26.1 mL/kg/min (bottom 10–25th percentile) — a major mortality predictor requiring immediate attention
Coronary CTA with HeartFlow Analysis
| Parameter | Result | Significance |
|---|---|---|
| CAC Score | 0 | No calcified plaque — but non-calcified plaque present |
| Total Plaque Volume | 8.4 mm³ (0.4% PAV) | Early disease — predominantly non-calcified (modifiable) |
| Non-Calcified Plaque | 7.6 mm³ in proximal LAD | Active plaque — confirms ASCVD diagnosis |
| Low-Density Plaque | 0 mm³ | No vulnerable plaque — disease is in modifiable phase |
| Greatest Stenosis | pLAD 6% (minimal) | Early — opportunity window for regression |
| CAD-RADS | 1/P1 | Minimal stenosis — but ASCVD now confirmed |
Advanced Lipid
| Marker | Result | Goal | Status |
|---|---|---|---|
| LDL Particle Number (LDL-P) | 1,443 nmol/L | < 1,000 | High — active atherogenic drive |
| Small LDL-P | 641 nmol/L | < 527 | Significantly elevated |
| LP-IR Score | 76 | < 45 | Insulin resistant — significant |
| ApoB | 99 mg/dL | < 60 mg/dL (ASCVD goal) | Needs aggressive reduction |
| Lp(a) | 88.3 nmol/L | < 75 nmol/L | Elevated — independent genetic risk |
| hs-CRP | 1.44 mg/L | < 1.0 mg/L | Elevated — active inflammation |
VO₂ Max, Body Composition & Epigenetics
| Metric | Value | Comment |
|---|---|---|
| VO₂ Max | 26.1 mL/kg/min | 10–25th percentile — strongly associated with elevated all-cause mortality |
| Body Fat % | 44% | Significantly elevated — chronic inflammatory and insulin-resistant state |
| Visceral Adipose Tissue | 2.75 lbs / 80.7 in³ | Significantly elevated — accelerates plaque formation |
| OMICm Age (Biologic) | 48.1 yrs | 8.3 years YOUNGER than chronological age — excellent cellular resilience |
| Fit Age | 60.3 yrs | 3.9 years OLDER — specific, correctable fitness gap |
| Hormone System Age | 63.5 yrs | Endocrine acceleration — linked to insulin resistance |
Treatment Initiated
High-intensity statin therapy was initiated targeting ApoB < 60 mg/dL and LDL < 55 mg/dL.
A GLP-1 receptor agonist was prescribed based on SELECT trial evidence demonstrating a 20% reduction in major adverse cardiovascular events in patients with established ASCVD and obesity. This is evidence-based cardiovascular medicine, not simply a weight loss intervention.
Blood pressure was optimized. The Pulse Perfect 360 Blueprint delivered a personalized VO₂ max improvement protocol, zone training prescription, Green Mediterranean nutrition framework, and a 90-day phased action plan.
Outcomes: Blood pressure optimized. Cholesterol improved. VO₂ max improved with the blueprint training protocol.
Key Clinical Teaching Point
What this case teaches us
- Female patients are systematically under-screened and under-treated in cardiovascular medicine. This patient had a 'normal echo' and was dismissed despite an abnormal EKG, elevated Lp(a), insulin resistance, 44% body fat, and early LAD plaque.
- A CAC score of zero does not mean no disease. This patient had a calcium score of zero and early non-calcified LAD plaque — confirming ASCVD and fundamentally changing her treatment targets.
- Lp(a) of 88.3 nmol/L is a largely genetic, independent cardiovascular risk factor present in approximately 20% of the population. It is never captured on a standard lipid panel and requires specific testing.
- VO₂ max of 26.1 mL/kg/min is in the lowest quartile for age and is strongly associated with increased all-cause mortality — more predictive than blood pressure, cholesterol, or diabetes status alone.
- GLP-1 receptor agonists (e.g., semaglutide) have demonstrated cardiovascular mortality reduction in patients with ASCVD and obesity — prescribing this medication in this context is evidence-based cardiology, not weight loss medicine.
- The epigenetic data revealed a striking contradiction: OMICm age 8 years younger than chronological age (excellent cellular resilience) but a fitness age 3.9 years older — a specific, correctable gap in physical conditioning.